Relmada Therapeutics, Inc. (RLMD) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Coral Gables, FL, United States. The current CEO is Sergio Traversa.
RLMD has IPO date of 2014-06-20, 17 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $527.27M.
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
